MeiraGTx Holdings plc (NASDAQ:MGTX) shares traded 1.62% higher at $6.29 on Wall Street last session.
In accordance with the data, 7 analysts cover MeiraGTx Holdings plc (NASDAQ:MGTX). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $47.00 and a low of $18.00, we find $27.00. Given the previous closing price of $6.19, this indicates a potential upside of 336.19 percent. MGTX stock price is now -21.88% away from the 50-day moving average and -37.73% away from the 200-day moving average. The market capitalization of the company currently stands at $292.17M.
It has been rated a hold by 0 analysts and a buy by 6. Brokers who have rated the stock have averaged $28.86 as their price target over the next twelve months.
With the price target of $27, RBC Capital Mkts recently initiated with Outperform rating for MeiraGTx Holdings plc (NASDAQ: MGTX). , while ‘Piper Jaffray’ rates the stock as ‘Overweight’.
In other news, Zeldin Robert K, CHIEF MEDICAL OFFICER bought 5,000 shares of the company’s stock on Jun 03. The stock was bought for $39,500 at an average price of $7.90. Upon completion of the transaction, the CHIEF MEDICAL OFFICER now directly owns 5,000 shares in the company, valued at $31450.0. An SEC document containing details of the transaction can be found on the SEC’s website. On May 25, GENERAL COUNSEL AND SECRETARY Wollin Robert J bought 1,000 shares of the business’s stock. A total of $7,940 was incurred on buying the stock at an average price of $7.94. This leaves the insider owning 1,000 shares of the company worth $6290.0. Insiders disposed of 181,211 shares of company stock worth roughly $1.14 million over the past 1 year. A total of 10.95% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in MGTX stock. A new stake in MeiraGTx Holdings plc shares was purchased by T. ROWE PRICE INVESTMENT MANAGEMENT, INC. during the first quarter worth $3,386,000. ATOM INVESTORS LP invested $132,000 in shares of MGTX during the first quarter. In the first quarter, MIRAE ASSET GLOBAL INVESTMENTS CO., LTD. acquired a new stake in MeiraGTx Holdings plc valued at approximately $86,000. OPALEYE MANAGEMENT INC. acquired a new stake in MGTX for approximately $63,000. ENSIGN PEAK ADVISORS, INC purchased a new stake in MGTX valued at around $31,000 in the second quarter. In total, there are 165 active investors with 66.70% ownership of the company’s stock.
MeiraGTx Holdings plc (NASDAQ: MGTX) opened at $6.16 on Monday. During the past 12 months, MeiraGTx Holdings plc has had a low of $5.70 and a high of $24.89. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 2.10, and a quick ratio of 2.10. The fifty day moving average price for MGTX is $8.05 and a two-hundred day moving average price translates $10.10 for the stock.
The latest earnings results from MeiraGTx Holdings plc (NASDAQ: MGTX) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.76, missing analysts’ expectations of -$0.64 by -0.12. This compares to -$0.59 EPS in the same period last year. The company reported revenue of $4.82 million for the quarter, compared to $6.95 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -30.69 percent. For the current quarter, analysts expect MGTX to generate $10.73M in revenue.
MeiraGTx Holdings plc(MGTX) Company Profile
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson’s diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson’s program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren’s syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company’s proprietary riboswitch technology. MeiraGTx Holdings plc was incorporated in 2015 and is based in New York, New York.